Seagen Archives -

News/ News/ News/ News/ Oncology/ R&D/ Sales and Marketing

Enhertu role in breast cancer confirmed, as Daiichi wins Seagen dispute

Phil Taylor antibody-drug conjugate, AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, Oncology, Seagen 0 Comment

AstraZeneca and Daiichi Sankyo have the confirmatory trial data they were hoping for with Enhertu as a treatment

Enhertu role in breast cancer confirmed, as Daiichi wins Seagen dispute

https://pharmaphorum.com/news/enhertu-role-in-breast-cancer-confirmed-as-daiichi-wins-seagen-dispute/

News/ News/ Sales and Marketing

Court won’t raise Seagen damages award in Enhertu patent dispute

Phil Taylor AstraZeneca, Daiichi Sankyo, Enhertu, patent litigation, Seagen 0 Comment

A Texas court has confirmed the $41.8 million damages awarded to Seagen in its patent dispute with Daiichi

Court won’t raise Seagen damages award in Enhertu patent dispute

https://pharmaphorum.com/news/court-wont-raise-seagen-damages-award-in-enhertu-patent-dispute/

Market Access/ News/ News/ News/ Oncology

AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu

Phil Taylor AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, EU, her2, Kadcyla, regulatory approval, Roche, Seagen, Tukysa 0 Comment

AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive

AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu

https://pharmaphorum.com/news/az-daiichi-challenge-roche-with-eu-okay-for-earlier-use-of-enhertu/

News/ News/ News/ Oncology/ Sales and Marketing

Merck in “advanced talks” for $40bn Seagen bid; report

Phil Taylor M&A, Merck & Co, Oncology, Seagen 0 Comment

The rumour that Merck & Co is preparing to make a sizeable offer to buy cancer specialist Seagen

Merck in “advanced talks” for $40bn Seagen bid; report

https://pharmaphorum.com/news/merck-in-advanced-talks-for-40bn-seagen-bid-report/

News/ News/ News/ News/ Oncology/ R&D/ Sales and Marketing

Is Merck planning a $30bn-plus move for Seagen?

Phil Taylor M&A, Merck & Co, Oncology, Seagen 0 Comment

Speculation that Merck & Co may be preparing a $30 billion takeover bid for Seagen – bolstering its

Is Merck planning a $30bn-plus move for Seagen?

https://pharmaphorum.com/news/is-merck-planning-a-30bn-plus-move-for-seagen/

News/ News/ Sales and Marketing

Seagen CEO on leave amid domestic abuse allegations

Phil Taylor Legal, Seagen, senior management 0 Comment

Seagen’s chief executive Clay Siegall has taken leave of absence pending an investigation into an alleged domestic violence

Seagen CEO on leave amid domestic abuse allegations

https://pharmaphorum.com/news/seagen-ceo-on-leave-amid-domestic-abuse-allegations/

News/ News/ Sales and Marketing

Seagen wins Enhertu patent dispute with Daiichi Sankyo

Phil Taylor antibody-drug conjugate, AstraZeneca, Daiichi Sankyo, Enhertu, patent litigation, Seagen 0 Comment

A US jury has decided that Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu infringes a patent held

Seagen wins Enhertu patent dispute with Daiichi Sankyo

https://pharmaphorum.com/news/seagen-wins-enhertu-patent-dispute-with-daiichi-sankyo/

News/ News/ Oncology

Trial win sets up new use for Astellas, Seagen’s Padcev in bladder cancer

Phil Taylor antibody-drug conjugate, Astellas, bladder cancer, Oncology, Padcev, Seagen 0 Comment

Astellas and Seagen’s Padcev is on course to move further up the treatment pathway in bladder cancer, thanks

Trial win sets up new use for Astellas, Seagen’s Padcev in bladder cancer

https://pharmaphorum.com/news/embargo-5pm-et-trial-win-sets-up-earlier-use-for-astellas-seagens-padcev/

Market Access/ News/ News

Seagen’s breast cancer drug Tukysa turned down by NICE

Phil Taylor breast cancer, HEOR, her2, NICE, Oncology, Seagen, Tukysa 0 Comment

NICE has decided not to recommend Seagen’s orally-active HER2 inhibitor Tukysa for advanced breast cancer in draft guidance,

Seagen’s breast cancer drug Tukysa turned down by NICE

https://pharmaphorum.com/news/seagens-breast-cancer-drug-tukysa-turned-down-by-nice/

Trending

Seagen

Login